Immunogenicity Information in Human Prescription Therapeutic Protein and Select Drug Product Labeling--Content and Format: Draft Guidance for Industry
Detailed guidance document from FDA and regulatory agencies.
Document Details
Guidance Document
February 3, 2022
February 4, 2025
7ecfa0a7-217f-451f-a5d5-0ffe4d7afd5d
Related Documents
Geriatric Information in Human Prescription Drug and Biological Product Labeling Guidance for Industry: Draft Guidance for Industry
Guidance DocumentSeptember 15, 2020Center for Drug Evaluation and Research
Drug Abuse and Dependence Section of Labeling for Human Prescription Drug and Biological Products — Content and Format Guidance for Industry
Guidance DocumentJuly 1, 2019Center for Drug Evaluation and Research
Dosage and Administration Section of Labeling for Human Prescription Drug and Biological Products — Content and Format
Guidance DocumentJanuary 12, 2023Center for Drug Evaluation and Research
Quick Actions
Transform Regulatory Data into Actionable Intelligence
Join leading pharmaceutical and medical device companies who trust GKS for their regulatory compliance needs.
Try KeyPedia Today
Explore our real use cases and discover our features in depth.
Subscribe to our newsletter
Get the latest updates and insights delivered to your inbox